Table of Contents
Chromatography Research International
Volume 2014, Article ID 258125, 8 pages
http://dx.doi.org/10.1155/2014/258125
Research Article

A Stability-Indicating High Performance Liquid Chromatographic Assay for the Simultaneous Determination of Pyridoxine, Ethionamide, and Moxifloxacin in Fixed Dose Combination Tablets

Department of Pharmaceutics, Faculty of Pharmacy, University of Karachi, Karachi 75270, Pakistan

Received 13 December 2013; Revised 17 February 2014; Accepted 12 March 2014; Published 23 April 2014

Academic Editor: Irene Panderi

Copyright © 2014 Munib-ur-Rehman et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Fattorini, D. Tan, E. Iona et al., “Activities of moxifloxacin alone and in combination with other antimicrobial agents against multidrug-resistant Mycobacterium tuberculosis infection in BALB/c mice,” Antimicrobial Agents and Chemotherapy, vol. 47, no. 1, pp. 360–362, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. K. Tahaoglu, T. Törün, T. Sevim et al., “The treatment of multidrug-resistant tuberculosis in Turkey,” The New England Journal of Medicine, vol. 345, no. 3, pp. 170–174, 2001. View at Google Scholar
  3. B. Ji, N. Lounis, C. Maslo, C. Truffot-Pernot, P. Bonnafous, and J. Grosset, “In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis,” Antimicrobial Agents and Chemotherapy, vol. 42, no. 8, pp. 2066–2069, 1998. View at Google Scholar · View at Scopus
  4. N. Lounis, A. Bentoucha, C. Trufoot-Pernot et al., “Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice,” Antimicrobial Agents and Chemotherapy, vol. 45, no. 12, pp. 3482–3486, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Yoshimatsu, E. Nuermberger, S. Tyagi, R. Chaisson, W. Bishai, and J. Grosset, “Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis,” Antimicrobial Agents and Chemotherapy, vol. 46, no. 6, pp. 1875–1879, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. H. R. Tucker, Dear Healthcare Provider Letter Regarding Reformulation of Trecator-SC (Ethionamide Sugar-Coated Tablets), Wyeth Pharmaceuticals, Philadelphia, Pa, USA, 2005.
  7. V. Selvapathy, “The prevention and treatment of isoniazid toxicity in the therapy of pulmonary tuberculosis,” Bulletin of the World Health Organization, vol. 28, pp. 455–475, 1963. View at Google Scholar
  8. T. Kirby, Medical News Today News Article, 2009.
  9. P. Young, M. C. Alonzo, and Maramba, Ethionamide (PIM 224), IARC Summary & Evaluation, vol. 13, 1977.
  10. P. R. Subbaiah, M. V. Kumudhavalli, C. Saravanan et al., “Method development and validation for estimation of moxifloxacin HCl in tablet dosage form by RP-HPLC method,” Pharmaceutica Analytica Acta, vol. 1, article 109, 2010. View at Google Scholar
  11. A. Dewani, B. B. Barik, S. K. Kanungo et al., “Development and validation of RP-HPLC method for the determination of moxifloxacin in presence of its degradation products,” American-Eurasian Journal of Scientific Research, vol. 6, no. 4, pp. 192–200, 2011. View at Google Scholar
  12. R. S. Chauhan, M. B. Chabhadiya, A. K. Patel et al., Simultaneous Estimation of Cefixime Trihydrate and Moxifloxacin Hydrochloride in Their Combined Tablet Dosage Form By RP-HPLC, 2013.
  13. M. Nawaz, “A new validated stability indicating RP-HPLC method for simultaneous estimation of pyridoxine hydrochloride and meclizine hydrochloride in pharmaceutical solid dosage forms,” Chromatography Research International, vol. 2013, Article ID 747060, 7 pages, 2013. View at Publisher · View at Google Scholar
  14. K. Nataraj, Y. Suvarna, and G. Venkateswari, “Development and validation of method for simultaneous estimation of pyridoxine hydrochloride and doxylamine succinate in tablet dosage form by first order derivative spectroscopy,” International Journal of Pharmacy & Pharmaceutical Sciences, vol. 5, no. 1, 2013. View at Google Scholar
  15. M. I. Walash, A. M. El-Brashy, M. E. S. Metwally, and A. A. Abdelal, “Fluorimetric determination of ethionamide in pharmaceutical preparations and biological fluids,” Journal of the Chinese Chemical Society, vol. 51, no. 5, pp. 1059–1064, 2004. View at Google Scholar · View at Scopus
  16. British Pharmacopoeia, Vol. I & II, London, UK, 2013.
  17. United States Pharmacopoeia, Vol. 35, December 2012.
  18. ICH, “Stability testing of new drug substances and products (Q1AR2),” in Proceedings of the International Conference on Harmonization, IFPMA, Geneva, Switzerland, 2003.
  19. ICH, Draft Guidelines on Validation of Analytical Procedures: Definitions and Terminology, Federal Register, vol. 60, IFPMA, Geneva, Switzerland, 1995.
  20. United States Pharmacopoeia, vol. 35, supplement II, December 2012.
  21. United States Pharmacopeia 32-NF 27, Chapter 1225, Validation of Compendial Procedures, Vol. 34, no. 3, pp. 794.
  22. S. Thomas, R. Kumar, A. Sharma, R. Issarani, and B. P. Nagori, “Stability-indicating HPLC method for determination of vitamins B1, B2, B3 and B6 in pharmaceutical liquid dosage form,” Indian Journal of Chemical Technology, vol. 15, no. 6, pp. 598–603, 2008. View at Google Scholar · View at Scopus
  23. A. P. Cione, E. Tonhi, and P. Silva, Stability Indicating Methods, Quality Control of Herbal Medicines and Related Areas, 2011.
  24. R. Singh and Z. Rehman, “Current trends in forced degradation study for pharmaceutical product development,” Journal of Pharmaceutical Education and Research, vol. 3, no. 1, pp. 54–64, 2012. View at Google Scholar
  25. A. Mohammadi, N. Rezanour, M. Ansari Dogaheh, F. Ghorbani Bidkorbeh, M. Hashem, and R. B. Walker, “A stability-indicating high performance liquid chromatographic (HPLC) assay for the simultaneous determination of atorvastatin and amlodipine in commercial tablets,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 846, no. 1-2, pp. 215–221, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Pistos, A. Tsantili-Kakoulidou, and M. Koupparis, “Investigation of the retention/pH profile of zwitterionic fluoroquinolones in reversed-phase and ion-interaction high performance liquid chromatography,” Journal of Pharmaceutical and Biomedical Analysis, vol. 39, no. 3-4, pp. 438–443, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Lemaire, P. M. Tulkens, and F. Van Bambeke, “Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 2, pp. 649–658, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Respaud et al., “High-performance liquid chromatography assay for moxifloxacin in brain tissue and plasma: validation in a pharmacokinetic study in a murine model of cerebral listeriosis,” Journal of Analytical Methods in Chemistry, vol. 2012, Article ID 436349, 7 pages, 2012. View at Publisher · View at Google Scholar
  29. J. Ermer, “Validation in pharmaceutical analysis. Part I: an integrated approach,” Journal of Pharmaceutical and Biomedical Analysis, vol. 24, no. 5-6, pp. 755–767, 2001. View at Publisher · View at Google Scholar · View at Scopus
  30. G. A. Shabir and T. K. Bradshaw, “Development and validation of a liquid chromatography method for the determination of methyl salicylate in a medicated cream formulation,” Turkish Journal of Pharmaceutical Sciences, vol. 8, no. 2, pp. 117–126, 2011. View at Google Scholar · View at Scopus
  31. D. M. Bliesner, Validating Chromatographic Methods: A Practical Guide, John Wiley & Sons, 2006.
  32. J. N. Miller and J. C. Miller, Statistics and Chemometrics for Analytical Chemistry, Prentice Hall, 2005.
  33. Z. Al-Kurdi, T. Al-Jallad, A. Badwan, and A. M. Y. Jaber, “High performance liquid chromatography method for determination of methyl-5-benzoyl-2-benzimidazole carbamate (mebendazole) and its main degradation product in pharmaceutical dosage forms,” Talanta, vol. 50, no. 5, pp. 1089–1097, 1999. View at Publisher · View at Google Scholar · View at Scopus
  34. Y. Vander Heyden, A. Nijhuis, J. Smeyers-Verbeke, B. G. M. Vandeginste, and D. L. Massart, “Guidance for robustness/ruggedness tests in method validation,” Journal of Pharmaceutical and Biomedical Analysis, vol. 24, no. 5-6, pp. 723–753, 2001. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Zeaiter, J.-M. Roger, V. Bellon-Maurel, and D. N. Rutledge, “Robustness of models developed by multivariate calibration. Part I: the assessment of robustness,” TrAC Trends in Analytical Chemistry, vol. 23, no. 2, pp. 157–170, 2004. View at Publisher · View at Google Scholar · View at Scopus